Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 8
2004 10
2005 14
2006 24
2007 31
2008 44
2009 38
2010 51
2011 51
2012 67
2013 71
2014 62
2015 46
2016 52
2017 61
2018 45
2019 46
2020 47
2021 57
2022 38
2023 34
2024 15

Text availability

Article attribute

Article type

Publication date

Search Results

702 results

Results by year

Filters applied: . Clear all
Page 1
Reply by Authors.
Lotan Y, Daneshmand S, Shore N, Black P, Scarpato KR, Patel A, Lough T, Shoskes DA, Raman JD. Lotan Y, et al. J Urol. 2024 May 10:101097JU0000000000004028. doi: 10.1097/JU.0000000000004028. Online ahead of print. J Urol. 2024. PMID: 38728316 No abstract available.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non-muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial.
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Narayan VM, et al. Among authors: lotan y. J Urol. 2024 May 5:101097JU0000000000004020. doi: 10.1097/JU.0000000000004020. Online ahead of print. J Urol. 2024. PMID: 38704840
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM; EDRN-PCA3 Study Group. Tosoian JJ, et al. JAMA Oncol. 2024 Apr 18. doi: 10.1001/jamaoncol.2024.0455. Online ahead of print. JAMA Oncol. 2024. PMID: 38635241
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry.
Ladi-Seyedian SS, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy With Cysview Registry Group. Ladi-Seyedian SS, et al. Among authors: lotan y. Cancers (Basel). 2024 Mar 24;16(7):1268. doi: 10.3390/cancers16071268. Cancers (Basel). 2024. PMID: 38610946 Free PMC article.
Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy.
Schroeck FR, Grubb R, MacKenzie TA, Ould Ismail AA, Jensen L, Tsongalis GJ, Lotan Y. Schroeck FR, et al. Among authors: lotan y. Eur Urol Open Sci. 2024 Mar 21;63:19-30. doi: 10.1016/j.euros.2024.02.018. eCollection 2024 May. Eur Urol Open Sci. 2024. PMID: 38558761 Free PMC article.
Alignment of molecular subtypes across multiple bladder cancer subtyping classifiers.
Reike MJ, de Jong JJ, Bismar TA, Boorjian SA, Mian OY, Wright JL, Dall'Era MA, Kaimakliotis HZ, Lotan Y, Boormans JL, Black PC, Gibb EA. Reike MJ, et al. Among authors: lotan y. Urol Oncol. 2024 Jun;42(6):177.e5-177.e14. doi: 10.1016/j.urolonc.2024.01.027. Epub 2024 Mar 12. Urol Oncol. 2024. PMID: 38480079
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer.
von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B; CLIPOLY Study Group Collaborators. von Deimling M, et al. Among authors: lotan y. BJU Int. 2024 Mar 12. doi: 10.1111/bju.16319. Online ahead of print. BJU Int. 2024. PMID: 38470089 Free article.
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, Lotan Y, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri N. Amara CS, et al. Among authors: lotan y. Nat Commun. 2024 Feb 14;15(1):1373. doi: 10.1038/s41467-024-45132-2. Nat Commun. 2024. PMID: 38355560 Free PMC article.
702 results